Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
1,800
Employees1,800
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
1,800
Employees1,800

NBIX Key Statistics

Market cap
10.04B
Market cap10.04B
Price-Earnings ratio
30.80
Price-Earnings ratio30.80
Dividend yield
Dividend yield
Average volume
2.17M
Average volume2.17M
High today
$102.05
High today$102.05
Low today
$99.09
Low today$99.09
Open price
$99.35
Open price$99.35
Volume
1.93M
Volume1.93M
52 Week high
$157.98
52 Week high$157.98
52 Week low
$84.23
52 Week low$84.23

NBIX News

TipRanks 1h
PepsiCo, Hormel, Neurocrine, Exelon, Aurora: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (PEP) ), ( (HRL) ), ( (NBIX) ), ( (EXC) ) and ( (AUR) ). Here is a breakdown of their recent ratings and the rationa...

Simply Wall St 1d
Do Neurocrine Biosciences' Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track...

Do Neurocrine Biosciences' Earnings Warrant Your Attention?
Benzinga 4d
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish

A physician survey for Neurocrine Biosciences Inc's NBIX Crenessity suggests "strong uptake across all patient segments," according to Needham. The Neurocrine...

Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish

Analyst ratings

81%

of 27 ratings
Buy
81.5%
Hold
18.5%
Sell
0%

More NBIX News

Benzinga 4d
This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
TipRanks 4d
Neurocrine upgraded to Buy from Hold at Needham

Needham analyst Ami Fadia upgraded Neurocrine (NBIX) to Buy from Hold with a $138 price target Published first on TheFly – the ultimate source for real-time, m...

TipRanks 5d
Neurocrine upgraded to Outperform at RBC Capital following pullback

As previously reported, RBC Capital upgraded Neurocrine (NBIX) to Outperform from Sector Perform with a price target of $137, down from $138. Weakness in the sh...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.